Ronald Vender

Feb 7, 2024 | nejm.org | Robert Bissonnette |Andreas Pinter |Laura K. Ferris |Ronald Vender

February 8, 2024N Engl J Med 2024; 390:510-521 DOI: 10.1056/NEJMoa2308713 AbstractThe use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23–receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.